December 2010
Accountancy;Dec2010, Vol. 146 Issue 1408, p55
Trade Publication
The author emphasizes the benefit of gastric surgery to severely obese people. She cites some of the diseases related to obesity including diabetes, heart disease and arthritis. She notes the withdrawal of anti-obesity drugs ribonamant and sibutramine from the market due to life-threatening side effects. She notes that gastric surgery compels individuals to reduce their food portion size.


Related Articles

  • Demise of sibutramine leaves EU doctors one obesity drug. Sayburn, Anna // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/30/2010, Vol. 340 Issue 7740, p233 

    The article reports on the decision of the European Medicines Agency to suspend the marketing authorisation for the weight loss drug sibutramine, as the U.S. Food and Drug Administration (FDA) decided to restrict its license due to concerns about raised risk of heart attacks and strokes.

  • The uphill battle facing antiobesity drugs. Daubresse, M; Alexander, G C // International Journal of Obesity;Mar2015, Vol. 39 Issue 3, p377 

    The authors reflect on the limited adoption of antibobesity drugs in clinical practice in the U.S. despite their association with short-term weight loss. They cite several antiobesity drugs that were withdrawn from the market due to the occurrence of adverse effects including sibutramine and...

  • Treating Diet-Induced Obesity: A New Role for Vagal Afferents? Fox, Edward // Digestive Diseases & Sciences;May2012, Vol. 57 Issue 5, p1115 

    No abstract available.

  • Responsible Weight Loss. Kline, Glaxo Smith // South African Pharmacist's Assistant;Autumn2011, Vol. 11 Issue 1, p38 

    The author discusses the need of overweight and obese individuals to be responsible in managing their weight. The author states that weight loss can be achieved through lifestyle modification such as regular exercise and the adoption of healthier diet. The author recommends that patients who are...

  • Clopidogrel.  // Reactions Weekly;1/21/2006, Issue 1085, p11 

    This article presents a case report of a male patient who developed acute polyarthritis during treatment with clopidogrel for coronary artery disease. It provides a background on the medical history of the patient. It offers information on the medication administered to the patient for acute...

  • Aspirin: foe or friend? Deas, Gerald W. // New York Amsterdam News;3/6/2008, Vol. 99 Issue 11, p32 

    The article offers information about Aspirin. Aspirin is an acetylsalicylic acid, which has been used for treating headaches, arthritis, fever and rheumatic fever. It is now one of the most important drugs in preventing strokes and heart attacks. Moreover, it can cause adverse reactions in the...

  • Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity. Farina, Maria; Baratta, Roberto; Nigro, Angela; Vinciguerra, Federica; Puglisi, Concetta; Schembri, Roberto; Virgilio, Clara; Vigneri, Riccardo; Frittitta, Lucia // Obesity Surgery;Apr2012, Vol. 22 Issue 4, p565 

    Background: Intragastric balloon (BioEnterics Intragastric Balloon, BIB®) or pharmacotherapy are possible options for the treatment of obese patients when traditional approaches have failed. The aim of our study was to compare in obese patients the effect on weight loss and metabolic changes...

  • Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet–exercise intervention. Bérubé-Parent, S; Prud'homme, D; St-Pierre, S; Doucet, E; Tremblay, A // International Journal of Obesity & Related Metabolic Disorders;Aug2001, Vol. 25 Issue 8, p1144 

    OBJECTIVE: Sibutramine favors a negative energy balance and also has the potential to increase heart rate and blood pressure. We investigated if a progressive supervised sibutramine-diet-exercise clinical intervention could increase the body weight loss previously reported while minimizing the...

  • Weight loss helps ailing kidneys.  // Clinical Advisor;Nov2009, Vol. 12 Issue 11, p12 

    The article reports on the literature review by nephrologist Sankar Navaneethan and colleagues on the benefits of surgical and nonsurgical weight-loss interventions to patients with chronic kidney disease (CKD). Reportedly, obesity is an independent risk factor of CKD. It cites that weight loss...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics